pAdTrack-CMV Search name
pAdTrack-CMV,Plasmid pAdTrack-CMV,pAdTrack-CMV vector
pAdTrack-CMV Information
Promoter: CMV promoter
Replicon: pUC ori
Terminator: SV40 poly (A) signal
Plasmid size: 9237bp
Prokaryotic resistance: Kan
Selection marker: Neo
Clone strain: Stbl3
Culture conditions: 37 C, aerobic, LB
Induction mode: no induction, instantaneous expression
pAdTrack-CMV Description
PAdTrack-CMV transgenic adenovirus vector to cell expression vector with CMV promoter and EGFP gene expression of green fluorescent protein tracking results, and use common pAdeasy1 vector maximum can be inserted into the 5.9kb, the use of common pAdeasy2 carrier can insert the 8.6kb. The specific use of the method can refer to the pAdeasy carrier system. Recombinant adenoviruses provide a versatile system for gene expression studies and therapeutic applications. We here report a strategy which simplifies the generation and production of such viruses. A recombinant adenoviral plasmid is generated with a minimum of enzymatic manipulations, employing homologous recombination in bacteria rather than in eucaryotic cells. Following transfections of such plasmids into a mammalian packaging cell line, viral production is conveniently followed with the aid of green fluorescent protein, encoded by a gene incorporated into the viral backbone. Homogeneous viruses can be obtained from this procedure without plaque purification.This system should expedite the process of generating and testing recombinant adenoviruses for a variety of purposes.
pAdTrack-CMV Multiple cloning site
pAdTrack-CMV Sequence
LOCUS Exported 9237 bp ds-DNA circular SYN 27-AUG-2016
DEFINITION synthetic circular DNA
KEYWORDS Untitled 3
SOURCE synthetic DNA construct
ORGANISM synthetic DNA construct
REFERENCE 1 (bases 1 to 9237)
TITLE Direct Submission
FEATURES Location/Qualifiers
source 1..9237
/organism="synthetic DNA construct"
/mol_type="other DNA"
repeat_region 79..181
/note="ITR"
/note="inverted terminal repeat of human adenovirus
serotype 5"
enhancer 3440..3743
/note="CMV enhancer"
/note="human cytomegalovirus immediate early enhancer"
promoter 3744..3947
/note="CMV promoter"
/note="human cytomegalovirus (CMV) immediate early
promoter"
polyA_signal 4158..4279
/note="SV40 poly(A) signal"
/note="SV40 polyadenylation signal"
enhancer 4365..4668
/note="CMV enhancer"
/note="human cytomegalovirus immediate early enhancer"
promoter 4669..4872
/note="CMV promoter"
/note="human cytomegalovirus (CMV) immediate early
promoter"
CDS 4917..5633
/codon_start=1
/product="enhanced GFP"
/note="EGFP"
/note="mammalian codon-optimized"
/translation="MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTL
KFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDD
GNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIK
VNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLL
EFVTAAGITLGMDELYK"
polyA_signal 5772..5893
/note="SV40 poly(A) signal"
/note="SV40 polyadenylation signal"
misc_signal 6036..6186
/note="Ad5 Psi"
/note="packaging signal for adenovirus serotype 5"
repeat_region 6274..6376
/note="ITR"
/note="inverted terminal repeat of human adenovirus
serotype 5"
rep_origin 6414..6794
/direction=RIGHT
/note="M13 ori"
/note="M13 bacteriophage origin of replication; arrow
indicates direction of (+) strand synthesis"
CDS complement(6842..7636)
/codon_start=1
/gene="aph(3')-II (or nptII)"
/product="aminoglycoside phosphotransferase from Tn5"
/note="NeoR/KanR"
/note="confers resistance to neomycin, kanamycin, and G418
(Geneticin(R))"
/translation="MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGRP
VLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDLLS
SHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDEEHQ
GLAPAELFARLKASMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRYQDIA
LATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF"
rep_origin 8468..9056
/direction=RIGHT
/note="ori"
/note="high-copy-number ColE1/pMB1/pBR322/pUC origin of
replication"
ORIGIN
1 agcgcctgat gcggtatttt ctccttacgc atctgtgcgg tatttcacac cgcatatgga
61 tccatgcatg ttaattaaca tcatcaataa tataccttat tttggattga agccaatatg
121 ataatgaggg ggtggagttt gtgacgtggc gcggggcgtg ggaacggggc gggtgacgta
181 ggttttaggg cggagtaact tgtatgtgtt gggaattgta gttttcttaa aatgggaagt
241 gacgtaacgt gggaaaacgg aagtgacgat ttgaggaagt tgtgggtttt ttggctttcg
301 tttctgggcg taggttcgcg tgcggttttc tgggtgtttt ttgtggactt taaccgttac
361 gtcatttttt agtcctatat atactcgctc tgcacttggc ccttttttac actgtgactg
421 attgagctgg tgccgtgtcg agtggtgttt ttttaatagg ttttcttttt tactggtaag
481 gctgactgtt atggctgccg ctgtggaagc gctgtatgtt gttctggagc gggagggtgc
541 tattttgcct aggcaggagg gtttttcagg tgtttatgtg tttttctctc ctattaattt
601 tgttatacct cctatggggg ctgtaatgtt gtctctacgc ctgcgggtat gtattccccc
661 gggctatttc ggtcgctttt tagcactgac cgatgtgaat caacctgatg tgtttaccga
721 gtcttacatt atgactccgg acatgaccga ggagctgtcg gtggtgcttt ttaatcacgg
781 tgaccagttt ttttacggtc acgccggcat ggccgtagtc cgtcttatgc ttataagggt
841 tgtttttcct gttgtaagac aggcttctaa tgtttaaatg tttttttgtt attttatttt
901 gtgtttatgc agaaacccgc agacatgttt gagagaaaaa tggtgtcttt ttctgtggtg
961 gttccggagc ttacctgcct ttatctgcat gagcatgact acgatgtgct ttcttttttg
1021 cgcgaggctt tgcctgattt tttgagcagc accttgcatt ttatatcgcc gcccatgcaa
1081 caagctattg aattcgttta aactccctct caagtctgta tacggggaca cggacagcct
1141 tttcgtcacc gagcgtggac accggctcat ggaaaccaga ggtaagaaac gcatcaaaaa
1201 gcatggggga aacctggttt ttgaccccga acggccagag ctcacctggc tcgtggaatg
1261 cgagaccgtc tgcggggcct gcggcgcgga tgcctactcc ccggaatcgg tatttctcgc
1321 gcccaagctc tacgccctca aaagtctgca ctgcccctcg tgcggcgcct cctccaaggg
1381 caagctgcgc gccaagggcc acgccgcgga ggggctggac tatgacacca tggtcaaatg
1441 ctacctggcc gacgcgcagg gcgaagaccg gcagcgcttc agcaccagca ggaccagcct
1501 caagcgcacc ctggccagcg cgcagcccgg agcgcacccc ttcaccgtga cccagactac
温馨提示:不可用于临床ZL。